Sovaldi and trelagliptin in latest Japanese approvals
This article was originally published in Scrip
Executive Summary
Japan has approved a batch of new drugs including Gilead's Sovaldi as part of the first all-oral therapy for HCV genotype 2 in the country, Eisai's Lenvima for thyroid cancer, and the world's first once-weekly DPP-4 inhibitor from Takeda.